Neurimmune Holdings AG
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurimmune Holdings AG
Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required By NIH
Pulling the controversial Alzheimer’s drug’s BLA should not exempt Biogen from fulfilling ClinicalTrials.gov reporting requirements for two key studies, even if the research gets terminated, former head of the NIH data repository tells the Pink Sheet.
Biogen Closes The Book On The Aduhelm Saga
Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial. Product’s legacy includes an FDA that appears less enthusiastic about accelerated approvals for large indications and a CMS that is more interested in label-driven reimbursement decisions.
Biogen Closes The Book On The Aduhelm Saga
Biogen will end the development and commercialization of Aduhelm, the first anti-amyloid antibody drug to reach the US market for Alzheimer’s, including the confirmatory ENVISION trial.
Swiss Talent And Innovation ‘Needs More Financing To Flourish’
With excellent academic centers and a thriving start-up scene, Switzerland’s biotech scene has garnered significant interest in recent years. However, without being a priority for EU funds, the sector remains reliant on foreign cash and needs a funding push from within to boost success.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- AL-S Pharma (joint venture)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice